Company profile: JuvLabs
1.1 - Company Overview
Company description
- Provider of biotech therapies and products to modify aging and address age-related diseases. Through its JuvRx therapeutics division, the company develops novel treatments targeting fibrosis and inflammatory conditions, including serpin-based PAI-1 inhibitors, TGF-β modulation drugs, NAD+ metabolism enhancers (with the Buck Institute), ketone-based therapies for heart failure, and an oral plasmalogen precursor to restore cell function.
Products and services
- JuvRx: A mechanism-focused therapeutics division that architects novel drugs targeting underlying drivers of age-related diseases, specifically fibrosis and inflammatory conditions, aiming for disease-modifying impact across multiple indications
- NAD+ Metabolism Program: A biochemical pathway-focused initiative that engineers therapies to elevate tissue NAD+ levels to address aging-related conditions, executed in collaboration with The Buck Institute for Research on Aging
- TGF-β Modulation Program: A pathway-targeted drug development effort that constructs therapeutics to modulate the TGF-β superfamily, aiming to treat diseases with high unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to JuvLabs
Synosia Therapeutics
HQ: Switzerland
Website
- Description: Provider of therapies for unmet medical needs in psychiatry and neurology. The privately-owned company develops and intends to commercialise products, with a pipeline of six clinical-stage compounds acquired through partnerships with Novartis, Roche and Syngenta. Two of the compounds are marketed drugs being tested in new indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synosia Therapeutics company profile →
Lundbeck
HQ: Denmark
Website
- Description: Provider of pharmaceuticals for psychiatric and neurological disorders, engaged globally in the research, development, production, marketing, and sale of these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lundbeck company profile →
Semnur Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical development focused on the clinical and commercial advancement of innovative products for pain management, including SP-102 (SEMDEXA), a non-opioid injectable corticosteroid gel designed to treat moderate to severe chronic radicular pain/sciatica via epidural injection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semnur Pharma company profile →
Convelo Therapeutics
HQ: United States
Website
- Description: Provider of novel remyelinating therapeutics that regenerate myelin in the central nervous system to restore function, supported by a proprietary screening platform that identifies candidates acting on oligodendrocyte progenitor cells, and a collaboration with Genentech to accelerate discovery and development of medicines for neurological disorders such as multiple sclerosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Convelo Therapeutics company profile →
Moberg
HQ: United States
Website
- Description: Provider of medical devices and neurodiagnostic solutions, including RetCam Envision pediatric ophthalmic imaging, Otoscan 3D ear scanning for auditory assessments, Natus NeuroWorks EEG analysis software, UltraPro S100 EMG/NCS/EP neurodiagnostic systems, and dedicated service and support for efficient workflows and optimal patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Moberg company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for JuvLabs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to JuvLabs
2.2 - Growth funds investing in similar companies to JuvLabs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for JuvLabs
4.2 - Public trading comparable groups for JuvLabs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →